On the same note, both TTN and nadir PSA have been implicated in patterns of progression and resistance to treatments across multiple treatment settings, including ARPI therapy, with rapid biochemical progression possibly indicating unique tumor biology in comparison to slow suppression of PSA [6,7,8]. This evidence concerns the gene KLK3 and neoplasm.